Engflag

Bomex

Quick links to important sections

Bomex

Bomex_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bomex

Quick Facts

Property Description
Active ingredient Brompheniramine Maleate
Form Tablets, Syrups, Extended-release capsules
Pharmacological class First-Generation Histamine H1 Antagonist
Common use Relief from general allergic symptoms
Origin Synthetic organic compound

What is Bomex? Defining the First-Generation Antihistamine

Bomex is the trade name for a medication whose active component is Brompheniramine Maleate, a synthetic compound classified as a first-generation antihistamine. This medication belongs to the Propylamine chemical class and functions as a Histamine H1 Antagonist, a classification that is widely and universally recognized by medical authorities.

The designation as a first-generation agent indicates that the compound is well-established, with its pharmacological properties supported by decades of clinical recognition for efficacy in symptom management. For instance, reviews confirm that Brompheniramine acts by competing with histamine at the H1-receptor sites on effector cells. This long-standing recognition establishes its authority in providing relief from acute allergic discomfort.

Composition and Available Forms of Brompheniramine Maleate

The active substance in this medication is consistently delivered as Brompheniramine Maleate, the stable salt form of Brompheniramine, which is engineered to ensure predictable solubility and absorption for effective systemic action. The drug is primarily intended for oral administration, meaning it is absorbed through the digestive tract.

Brompheniramine Maleate is manufactured in various common dosage forms to accommodate diverse patient needs, including conventional tablets, liquid syrups, and specialized extended-release capsules. The availability across these forms facilitates the reliable delivery of the active ingredient, distinguishing its comprehensive presentation across various administration requirements.

The General Purpose: Relief from Allergic Symptoms

The general purpose of this medication is to provide effective, high-level relief from the symptoms caused by various allergic conditions by executing its Histamine H1 receptor blockade. The compound is recognized for its general effectiveness in decreasing symptoms typical of conditions like seasonal rhinitis.

By preventing histamine from activating its target receptors, the drug directly addresses the physiological cause of discomfort, resulting in the mitigation of acute symptoms. Its use is clinically recognized for easing common manifestations, such as persistent sneezing, excessive nasal discharge, eye watering, and localized itching of the throat or nose. Its primary role is defined as an anti-allergic agent focused on symptomatic relief.

Regulatory References

  1. NIH DailyMed
  2. MedlinePlus Drug Information

What side effects are possible with Bomex?

Possible side effects and safety information

Official Regulatory Safety Profile

The officially documented safety profile for this medication (Bumetanide) is defined by its potent action on fluid and electrolyte balance. Adverse reactions are classified by frequency and system-organ class in regulatory documents, with the most characteristic effects linked to fluid loss.

Frequency-Classified Adverse Reactions

Classification Common Adverse Reactions (Examples) Uncommon Adverse Reactions (Examples)
Effects Dizziness, headache, nausea, muscle cramps, hypokalemia, hyponatremia, hyperuricemia, dehydration. Hypotension, vomiting, hearing disturbances, chest discomfort, rash.
System Classes Metabolism and Nutrition Disorders, Nervous System Disorders. Vascular Disorders, Gastrointestinal Disorders, Ear and Labyrinth Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory information notes the potential for profound diuresis, which can lead to serious volume and electrolyte depletion and the risk of circulatory collapse. Hepatic encephalopathy is documented as a serious concern, particularly in patients with pre-existing liver disease. Cases of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome, have also been reported.

Population-Specific Safety Notes

Safety statements in regulatory labels address specific groups. Older adults may be more susceptible to profound fluid loss and associated complications. For patients with hepatic cirrhosis, small doses and careful management are noted as necessary, as sudden electrolyte changes may precipitate encephalopathy. The medication is officially contraindicated in states of severe electrolyte depletion and hepatic coma.

The diuretic action is rapid, typically completing its primary effect within approximately four hours, which frames the period during which the most significant fluid changes occur. The overall safety structure emphasizes the management of fluid and electrolyte status as the core constraint of the treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Bomex (Brompheniramine Maleate) describe the manifestations of overdose across the Central Nervous System (CNS) and cardiovascular system. Documented signs include CNS effects ranging from drowsiness and loss of consciousness to agitation and convulsions, depending on the exposure level. Systemic effects, known as anticholinergic symptoms, often present with dilated pupils, dry mouth, and inability to urinate.

Severe Outcomes and Emergency Action

Severe or life-threatening outcomes are explicitly documented, including coma, cardiac arrhythmias (irregular heartbeat), and hyperthermia. Regulatory sources note that overdosage in infants and small children carries a distinct risk for hallucinations, seizures, and death, while the elderly are more prone to toxic confusional states and excessive sedation.

In the event of suspected overdose, official guidance mandates that individuals seek immediate medical attention and contact emergency services. Since no specific antidote is available, management is defined as strictly symptomatic and supportive.

Management and Monitoring Requirements

Regulatory sources outline specific procedures such as administering activated charcoal and gastric lavage in a hospital setting. Continuous hospital monitoring, including an Electrocardiogram (ECG), is required to assess and manage severe cardiovascular and neurological complications.

Therapeutic Uses of Bomex

What Bomex Treats: Main Uses and Benefits

Bomex (bumetanide) is a prescription medication utilized in a therapeutic regimen to manage fluid retention, a condition commonly referred to as edema. The administration of this medication is indicated for individuals who present with excess fluid associated with specific underlying medical conditions.

Quick Facts

  • Supports the management of fluid retention (edema) associated with congestive heart failure.
  • Aids in addressing fluid accumulation stemming from certain liver diseases.
  • Applicable in therapeutic contexts involving fluid retention associated with various forms of renal (kidney) disease, including nephrotic syndrome.

The core benefit of Bomex is to facilitate the removal of unneeded water and salt from the body via the kidneys, promoting increased urine output. This action helps to reduce the volume of excess fluid that has built up in body tissues, such as the legs, ankles, or lungs. It is employed as a component of treatment plans for fluid retention linked to:

  • Specific conditions of the heart, such as congestive heart failure.
  • Underlying issues with liver function.
  • Defined kidney diseases.

Bomex is a medically supervised treatment; it is not a curative measure for the underlying conditions. Clinical use and safety parameters are standard components of the treatment profile.

Eligibility and Restrictions for Use

Bomex (Bumetanide) is strictly governed by regulatory eligibility rules established by health authorities. These rules define the populations permitted to use the medicine and those who are formally prohibited or require special caution due to specific health conditions. The eligibility profile is based entirely on official documentation, such as Prescribing Information and Summaries of Product Characteristics.

Eligibility Scope: Official Regulatory Status

Eligibility Scope Regulatory Statement
Populations for whom use is contraindicated Patients with persisting anuria, established hepatic coma or hepatic encephalopathy, or a history of hypersensitivity to the drug.
Age-related eligibility rules Use is approved for adults. Safety and efficacy have not been established in the pediatric population; therefore, use is not recommended for children under 12 years of age. Older adults require caution.
Condition-specific eligibility rules Use is restricted in severe renal impairment (discontinuation may be required if renal function worsens) and severe hepatic impairment (caution is essential due to the risk of precipitating coma).
Pregnancy and lactation eligibility status Pregnancy: Should generally not be used unless the clinical benefit is judged to outweigh the documented risks. Lactation: Use is not recommended; mothers must discontinue nursing or the medication.

Eligibility Classifications (High-Level)

Classification Regulatory Basis
Eligibility severity classification Contraindicated, Not Recommended, Use Not Established, Use with Caution
Eligibility-context constraints Organ function limitations (anuria, hepatic disease), Age thresholds, and Hypersensitivity

Connection to the overall eligibility profile: The official eligibility profile for this medication is defined by clear, mandatory contraindications related to major organ failure, primarily involving the kidneys and liver. For populations where use is not prohibited, regulators mandate the need for special caution when preexisting conditions, such as age or specific organ impairment, are present.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Bomex (Bumetanide) is defined by official regulatory documents through specific pharmacodynamic and pharmacokinetic constraints. Contraindications are formally listed for specific medical states, including Anuria, Hepatic coma, and Severe electrolyte depletion, until the condition is corrected.

Documented Pharmacological Interactions

Interaction Type Interacting Agents / Substances
Toxicity Potentiation Ototoxic drugs (e.g., Aminoglycosides) have their risk of ototoxicity increased. Nephrotoxic drugs may also carry an increased risk of toxicity.
Exposure and Clearance Lithium clearance is reduced, leading to increased serum levels and risk of toxicity. Probenecid inhibits renal tubular secretion, diminishing the diuretic effect.
Pharmacodynamic Effects Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) antagonize the diuretic action. Antihypertensive agents and Alcohol may cause additive hypotensive effects.

Population and Dietary Considerations

Population-specific notes documented in labeling include a heightened ototoxicity risk in patients with renal impairment and the potential for bilirubin displacement in critically ill neonates. High sodium intake can antagonize the drug's therapeutic effect, reducing its efficacy.

Mechanism of Action

The mechanism of action for Bomex (Brompheniramine Maleate) is defined by its targeted action on two major receptor systems, resulting in the modulation of specific physiological responses.

Histamine Receptor Antagonism

This domain focuses on the molecule's principal action as a competitive antagonist (inverse agonist) at peripheral Histamine H1 Receptors ( H1 R). By occupying the H1 R binding site, the drug prevents the inflammatory mediator, histamine, from initiating the G q-mediated signaling cascade. This mechanism modifies the molecular steps that typically lead to increased vascular permeability and sensory nerve stimulation, resulting in the physiological consequence of decreased vascular permeability and diminished sensory nerve firing.

Cholinergic and CNS System Modulation

This domain encompasses the drug's activity outside of the H1 R system, owing to its chemical structure and lipophilicity. The molecule exhibits antagonist activity at Muscarinic Acetylcholine Receptors on exocrine glands, which mechanistically inhibits cholinergic signal transmission and reduces glandular secretions. Concurrently, the drug crosses the blood-brain barrier to block H1 R in the CNS, directly engaging the histaminergic pathways that regulate arousal, leading to a change in the state of alertness.

Dosage and Administration Information

How Bomex is Administered

The use of Bomex (Bumetanide) involves specific administration routes, schedules, and dosage ranges. The primary route of administration is oral, typically starting with a dose of 0.5 mg to 2 mg once per day. This initial amount can be taken with or without food. If the diuretic effect is not sufficient, the dose may be repeated at 4- to 5-hour intervals; however, the total daily amount does not exceed a maximum dosage of 10 mg.

For practical use, the oral dose is generally taken in the morning to prevent nocturnal diuresis. For the long-term control of chronic edema, an intermittent schedule is used, where the medicine is administered for a few days followed by rest periods.

The medication is also available for parenteral administration (intravenous or intramuscular), but this route is usually reserved for patients with compromised gastrointestinal absorption or when oral intake is impractical. When given intravenously, the injection is administered slowly over a period of 1 to 2 minutes.

Specific adjustments are utilized for certain populations. Due to potential changes in drug clearance, dosing for older adults is initiated cautiously at the low end of the prescribed range. For patients with hepatic impairment, the dosage is also minimized. The safety and effectiveness of Bomex have not been established in pediatric patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bomex

Evidence for Use in Fluid Retention Associated with Heart Failure

Research exploring the use of Bomex in fluid retention, or edema, in adults with congestive heart failure is extensive. This research has involved comparative clinical trials and observational studies that have explored the medication as a diuretic. The studies monitored outcomes related to fluid balance, such as diuresis (urine output) and natriuresis (sodium excretion), as well as physical measures like changes in body weight and measures of peripheral swelling. Findings describe patterns observed in the studies where individuals demonstrated changes in fluid balance consistent with observed physiological effects. The research documents that the absorption of the oral form may also be variable in individuals with very severe heart failure.

Evidence for Use in Fluid Retention Due to Liver Disease

The research base for Bomex also was studied for its use in fluid buildup, including both peripheral edema and ascites (fluid in the abdomen), in individuals with liver conditions such as cirrhosis. Comparative clinical trials and short-term response studies have examined how the medication affects fluid balance in this specific population. Clinical reports describe patterns related to the rate and speed of observed fluid-balance changes within specific timeframes across study cohorts. Evidence is limited regarding the long-term, independent contribution of Bomex in the overall context of liver disease, as it is often administered alongside other medications.

Evidence for Use in Fluid Retention Due to Kidney Disease

The medication was evaluated in patients experiencing edema secondary to various kidney diseases, including specific groups with severe renal impairment. Research in this area includes crossover designs and dose-response studies which explore how the medication works across a range of kidney functions. The outcomes monitored in these trials were diuresis, natriuresis, and body weight change, alongside measurements in relation to markers of kidney function. Research describes that complex fluid and electrolyte monitoring was required when studying patients with severe kidney impairment. The existing research provides limited information for long-term outcomes regarding the use of these fluid-removal methods and the underlying condition.

What is Still Under Study or Uncertain

Research highlights what is known and what is still uncertain regarding the medication’s use. A primary gap is the limited information for long-term outcomes beyond symptomatic fluid assessment, such as the relationship between medication use and the long-term progression of underlying cardiac or renal diseases. Furthermore, comparative evidence is lacking for some of the more complex patient subgroups. Studies may also show variability in patient response due to differences in underlying disease severity and fluid absorption.

Key Studies & References

  1. A comparison of bumetanide and furosemide in the treatment of ascites. Cooperative study.
  2. Long-term bumetanide treatment of patients with edema due to renal disease. Cooperative studies.

Frequently Asked Questions (FAQ)

Common questions about Bomex (FAQ)

Q: Is it true that Bomex can cause weight changes?

Official documentation notes that changes in body weight, including sudden weight gain or rapid weight loss, are monitored during treatment with Bomex (Bumetanide). These changes can indicate fluid status shifts, which the medicine is intended to manage. Unexplained weight loss is also listed as a side effect in regulatory documents.

Q: What should I know about taking Bomex if I have liver problems?

Use of Bomex (Bumetanide) is formally contraindicated for patients experiencing established hepatic coma. For individuals with severe liver impairment, official documents emphasize the need for caution. This is because sudden fluid or electrolyte changes caused by the drug may increase the risk of a serious condition called hepatic encephalopathy.

Q: Are there any common over-the-counter medicines that interact with Bomex?

Regulatory labeling indicates known interactions with certain common over-the-counter products, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, as well as products that are high in sodium. Regulatory documents also contain separate warnings regarding the combination of Bomex with alcohol and other medicines that cause central nervous system depression.

Q: How long does it typically take to notice the expected effects of Bomex?

For the diuretic component of Bomex (Bumetanide), the primary effect on fluid removal usually begins relatively quickly after the dose is taken. This primary effect is generally complete within about four hours, according to official prescribing information.

Q: What happens if I stop taking Bomex suddenly?

Official information states that stopping the use of Bomex (Bumetanide) may cause fluid to build up in the body again, leading to a return of swelling (edema). Changes to one's course of therapy are addressed in the labeling, which stresses the importance of consulting a healthcare provider before stopping the medicine.

Q: Is Bomex meant for long-term use?

Bomex (Bumetanide) is described in regulatory guidance as potentially being used for an extended period, depending on the nature of the condition it is used to manage. This can include long-term therapy, as noted in official documents.

Q: What is the risk of dependence or addiction associated with Bomex?

Bomex (Bumetanide) is officially classified as a non-controlled medication by the U.S. Drug Enforcement Administration. The drug's non-controlled status means it is not designated as a scheduled substance.

Q: Is Bomex safe to take during pregnancy?

Official prescribing information indicates that Bomex should generally not be used during pregnancy. Use is restricted by regulators to situations where the potential benefit is judged to outweigh the documented risks. The label notes that animal studies have shown adverse effects on the fetus.

Q: Are there any real-world studies about the long-term effects of Bomex?

Regulatory overviews of studies acknowledge that there is limited information available regarding the long-term outcomes of Bomex use. The existing evidence primarily focuses on the immediate or short-term symptomatic management of fluid status, and information is limited regarding the long-term effects on the underlying conditions.

Q: Is Bomex available in different strengths or forms (like tablets vs liquid)?

Yes, Bomex is manufactured in different forms for oral administration, including conventional tablets, liquid syrups, and extended-release capsules. The available tablet strengths for Bomex (Bumetanide) are officially documented as 0.5 mg, 1 mg, and 2 mg.

Q: Does Bomex have any food interactions mentioned in the official labeling?

Official documents state that Bomex (Bumetanide) can be taken with or without food. A key note, however, is that high salt (sodium) intake can antagonize the drug's action and is documented in official labeling as potentially reducing the medicine's efficacy.

Q: Is Bomex available as a generic medicine?

Yes, regulatory records confirm that a generic version of the active ingredient, Bumetanide, is available.

Q: If I am taking supplements, should I be concerned about using Bomex?

Official regulatory information advises caution when taking herbal products or supplements alongside Bomex due to the limited research on potential interactions. Specific caution is noted for supplements that may affect potassium levels or contain high amounts of caffeine.

Q: What are the signs of an allergic reaction to Bomex?

Official safety documentation notes that signs of a serious allergic reaction may include rash, hives, swelling of the face, lips, tongue, or throat, and difficulty breathing. These reactions are documented in regulatory information.

Q: Can older adults use Bomex without special monitoring?

Regulatory guidance indicates that dosing for older adults should be initiated cautiously, as they may be more susceptible to the medicine's effects and complications, such as profound fluid loss and confusion. The label emphasizes the need for careful supervision and monitoring in this population.

Q: What are the official warnings associated with Bomex?

The drug’s official labeling includes a serious warning regarding the potential for profound diuresis (excessive urination). This can lead to severe water and electrolyte depletion. Other serious adverse events noted in the regulatory documents include hearing disturbances (ototoxicity) and hepatic encephalopathy.

Q: What kind of monitoring is typically recommended while taking Bomex?

Patients taking Bomex (Bumetanide) are typically monitored for changes in blood pressure, body weight (fluid status), kidney function, and the levels of key electrolytes such as potassium and sodium. These checks are documented as necessary to ensure appropriate management.

Q: What research is currently being done on Bomex?

Official records, such as those registered with government clinical trial databases, indicate that research is currently examining the medication's use in different populations. This includes studying its action in relation to other fluid-removing methods (diuretics) in conditions like heart failure.

Q: What does it mean if Bomex is a 'Schedule X' drug?

Bomex (Bumetanide) is officially classified as a non-controlled substance by the U.S. Drug Enforcement Administration. The drug is not designated as a scheduled drug, which is a classification reserved for substances with a recognized potential for abuse.

Q: Can Bomex make existing medical conditions worse?

Yes, official safety information notes that Bomex (Bumetanide) may potentially worsen certain pre-existing conditions. These conditions include dehydration, gout, and severe impairment of kidney or liver function.

Q: How does the official labeling describe stopping Bomex therapy?

Official documents state that individuals should not stop taking the medicine without first consulting their healthcare provider. The reason for this caution is the risk that stopping the therapy may lead to a recurrence of fluid buildup (edema).

Q: Does Bomex carry any warnings related to mental health conditions?

Warnings are present regarding effects on the Central Nervous System (CNS), which may include diminished mental alertness, confusion, and nervousness. These effects are noted as potential adverse reactions in the official labeling.

Q: What are the most commonly reported side effects of Bomex?

The most commonly reported side effects across regulatory documents include headache, dizziness, nausea, muscle cramps, and low levels of potassium (hypokalemia). For the antihistamine component (Brompheniramine), sedation and dry mouth are also frequently reported.

Q: Can Bomex cause stomach issues or nausea?

Yes, official safety information includes gastrointestinal issues among the reported adverse reactions. These commonly reported effects can include nausea, vomiting, diarrhea, constipation, and stomach cramps.

Q: Does alcohol have an interaction with Bomex?

Yes, regulatory information notes that alcohol may cause additive effects. This can increase the risk of low blood pressure (hypotension) with Bumetanide or cause increased drowsiness and dizziness with Brompheniramine.

Q: What is a 'contraindication' for Bomex?

A contraindication is a regulatory term for a condition or factor that prohibits the use of a medicine because it may cause harm. For Bomex, contraindications officially include anuria (inability to urinate) and established hepatic coma.

Q: How is the 'mechanism of action' for Bomex generally described?

The drug's general function is described by its two main active ingredients. Bomex (Bumetanide) is a diuretic (a 'water pill') that works in the kidneys to remove excess salt and water. The antihistamine component (Brompheniramine) works by blocking the action of histamine in the body to relieve allergy symptoms.

Q: Does taking Bomex affect my ability to drive or operate machinery?

Yes, both active components carry warnings regarding activities that require mental alertness. Side effects such as dizziness, faintness due to blood pressure changes (Bumetanide), and drowsiness (Brompheniramine) mean patients are officially advised to be cautious when driving or operating heavy machinery.

How should Bomex be stored and disposed of?

Official Storage and Disposal Profile

Official regulatory guidelines for prescription medications, particularly those classified as controlled substances, establish mandatory rules for storage and final disposal.

Storage and Handling

  • Security: To prevent unauthorized access or diversion, this medication must be stored in a locked cabinet, safe, or receptacle reserved specifically for poisons or psychotropic substances.
  • Environment: Containers shall be light-resistant and include consumer safety caps to maintain drug stability and restrict access, and the product should generally be kept in a cool, dry place.
  • Stability: The official label defines the shelf life after first opening or reconstitution, which must be strictly followed.

Disposal Instructions

  • Official Return: Unused or expired medication must be returned to a designated pharmacy take-back facility or other official collection program.
  • Controlled Waste: Disposal of certain controlled components is mandated to occur in the presence and according to the instruction of a Drug Enforcement Officer.
  • Segregation: Related materials, such as expired product or used sharps, are classified as clinical waste and must be segregated into designated waste containers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bomex found in:

A-Z Index: